PRL and prostate cancer: In breast (Abdelmagid and Too, 2008) and prostate cancers, CPD is upregulated by hormones including prolactin, estrogen, and testosterone, driving oncogenic effects through promoting NO generation and enhancing tumor cell survival (Thomas et al., 2012).